Tempus AI competitors, on the record
The companies Tempus AI names as competitors in its annual reports, 2024 to 2025, and the companies that name Tempus AI, each with the sentence and the filing.
Who Tempus AI names
| Company | Named in |
|---|---|
| Anumana, Inc. | 2025 |
| Baylor Genetics | 2025 |
| Caris Life Sciences | 2025 |
| ConcertAI | 2025 |
| Eko Devices, Inc. | 2025 |
| Flatiron Health, Inc. | 2025 |
| Fortrea | 2025 |
| Foundation Medicine, Inc. | 2025 |
| GeneDx | 2025 |
| Genomind, Inc. | 2025 |
| Guardant Health, Inc. | 2025 |
| HeartFlow Inc. | 2025 |
| ICON | 2025 |
| Illumina, Inc. | 2025 |
| IQVIA Holdings Inc. | 2025 |
| LabCorp | 2025 |
| Myriad Genetics, Inc. | 2025 |
| Natera | 2025 |
| Neogenomics | 2025 |
| PathAI, Inc. | 2025 |
| PPD | 2025 |
| Quest | 2025 |
| ResolutionBio | 2025 |
| Roche Holdings, Inc. | 2025 |
| Syneos | 2025 |
| Variantyx | 2025 |
In its own words
Anumana, Inc.
Word for word“In cardiology, we believe our competitors may include HeartFlow Inc., Anumana, Inc., and Eko Devices, Inc.” 10-K for 2025
Baylor Genetics, GeneDx, Variantyx
Word for word“Our primary competitors for our hereditary tests include GeneDx, Variantyx, and Baylor Genetics.” 10-K for 2025
Caris Life Sciences, Foundation Medicine, Inc., Guardant Health, Inc., Natera, Neogenomics, ResolutionBio
Word for word“Our primary competitors for our currently marketed precision oncology tests include Foundation Medicine, Inc., which was acquired by Roche Holdings, Inc., Caris Life Sciences, Guardant Health, Inc., Natera, Neogenomics, ResolutionBio, which was acquired by Agilent, and others.” 10-K for 2025
ConcertAI, Flatiron Health, Inc., IQVIA Holdings Inc.
Word for word“Our main competitors in this area are Flatiron Health, Inc., IQVIA Holdings Inc., ConcertAI, and others.” 10-K for 2025
Eko Devices, Inc., HeartFlow Inc.
Word for word“In cardiology we may compete with companies such as HeartFlow Inc. and Eko Devices, Inc.” 10-K for 2025
Fortrea, ICON, PPD, Syneos
Word for word“Our Data and applications products also face competition from CROs, such as Fortrea, ICON, Syneos, PPD, and others, who provide data and clinical trial matching services to pharmaceutical and biotechnology companies.” 10-K for 2025
Genomind, Inc., Myriad Genetics, Inc.
Word for word“Competitors for our pharmacogenetic test in neuropsychiatry include Myriad Genetics, Inc. and Genomind, Inc.” 10-K for 2025
Illumina, Inc.
Word for word“Our competitors with respect to our Applications products include Roche Holdings, Inc., Caris Life Sciences, Guardant Health, Inc., Illumina, Inc., and others, with respect to our TO test, and Myriad Genetics, Inc., Caris Life Sciences, and others, with respect to our HRD test.” 10-K for 2025
LabCorp, Quest
Word for word“Legacy diagnostic laboratories, such as Quest and LabCorp may also pose competitive threats within the market.” 10-K for 2025
PathAI, Inc.
Word for word“We may also compete with companies developing or commercializing algorithm-based diagnostics using a variety of different data modalities, including digital pathology companies such as PathAI, Inc.” 10-K for 2025
Roche Holdings, Inc.
Word for word“With respect to Algos, our TO test competes with liquid or tissue-based diagnostic tests from Roche Holdings, Inc., Caris Life Sciences, Guardant Health, Inc. Illumina, Inc, and others.” 10-K for 2025
Who names Tempus AI
Companies whose own annual reports name Tempus AI as a competitor.
Word for word“Each of Natera, Tempus AI, Guardant, NeoGenomics, Myriad Genetics, Inc., Quest Diagnostics, and Personalis have commercially available competitive MRD tests or have such tests in development, which currently or may in the future compete directly with our Oncodetect MRD test.” 10-K for 2025
Read from Tempus AI’s annual reports (10-K for 2025, 10-K for 2024) and the financial data it files with the SEC, as of 2026-02-24. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.